Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in Liver
Open Access
- 29 February 2000
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 1 (2), 154-158
- https://doi.org/10.1006/mthe.2000.0031
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarizationNature Medicine, 1999
- Persistent expression of canine factor IX in hemophilia B caninesGene Therapy, 1999
- Enhanced Expression of Transgenes from Adeno-Associated Virus Vectors with the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element: Implications for Gene TherapyHuman Gene Therapy, 1999
- Gene therapy for the hemophiliasProceedings of the National Academy of Sciences, 1999
- Adeno-Associated Virus Vectors and HematologyBlood, 1999
- Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophiliaGene Therapy, 1998
- Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsNature Genetics, 1997
- Gene therapy for the hemophiliasPublished by Elsevier ,1997
- Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs.Proceedings of the National Academy of Sciences, 1990
- Canine hemophilia B resulting from a point mutation with unusual consequences.Proceedings of the National Academy of Sciences, 1989